CMMB

Chemomab Therapeutics Ltd. (CMMB) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.4 (Moderate)

Publicly available disclosures provide limited environmental detail versus larger biotech peers, constraining comparability on emissions, energy use, and waste management practices.

As a development-stage healthcare company, CMMB’s direct operational footprint is typically smaller than manufacturing-heavy peers, but disclosure depth remains thinner than best-in-class issuers.

No material environmental controversies are evident in the provided information, yet the absence of robust targets and metrics limits evidence of peer-leading environmental management.

Relative to peers with more comprehensive sustainability reporting, CMMB appears neutral to slightly weaker on environmental transparency rather than on demonstrated operational impact.

Social

Score:

CMMB’s social positioning is constrained by limited disclosed data on patient safety, clinical governance, and workforce practices compared with more transparent healthcare peers.

In a regulated healthcare context, stronger peer disclosures on trial conduct, product stewardship, and quality systems typically support higher social scores than CMMB’s sparse reporting.

The provided metrics do not indicate elevated social controversy, but they also do not evidence differentiated labor, diversity, or community practices versus peers.

Overall social performance appears broadly average relative to peers, with disclosure gaps preventing a stronger assessment of stakeholder management quality.

Governance

Score:

Governance appears mixed because the provided metrics show no leverage stress, yet they do not address board independence, audit quality, or shareholder protections.

Compared with better-governed peers, CMMB’s limited governance disclosure reduces confidence in oversight effectiveness and long-term accountability.

The absence of reported stock-based compensation pressure is a modest positive, but it is insufficient to offset the lack of visible governance detail.

Relative to peers, CMMB looks neither structurally weak nor clearly strong on governance, with transparency remaining the main constraint.

Overall Score

Score:

CMMB’s ESG profile is moderate relative to peers because limited disclosure across environmental, social, and governance dimensions outweighs the absence of clear material controversies.

Score Driver: Limited ESG Disclosure Transparency Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Chemomab Therapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →